Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

How to buy Xencor stock

Learn how to easily invest in Xencor stock.

Xencor Inc is a biotechnology business based in the US. Xencor shares (XNCR) are listed on the NASDAQ and all prices are listed in US Dollars. Xencor employs 254 staff and has a trailing 12-month revenue of around $289.4 million.

How to buy shares in Xencor

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – XNCR – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.
Client disclaimer: US Brokerage services through eToro USA Securities Inc, member of FINRA, SIPC. Crypto assets through eToro USA LLC.

Xencor stock price (NASDAQ: XNCR)

Use our graph to track the performance of XNCR stocks over time.

Xencor shares at a glance

Information last updated 2022-10-03.
Latest market close$25.83
52-week range$19.36 - $43.61
50-day moving average $28.04
200-day moving average $29.17
Wall St. target price$48.25
PE ratio 70.2162
Dividend yield $0 (0%)
Earnings per share (TTM) $0.37

Buy Xencor shares from these brokerages

Compare special offers, low fees and a wide range of types of investments among top trading platforms.
1 - 6 of 6
Name Product Asset types Stock trade fee Minimum deposit Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.

Compare up to 4 providers

*Signup bonus information updated weekly.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Is it a good time to buy Xencor stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Xencor price performance over time

Historical closes compared with the close of $25.83 from 2022-10-03

1 week (2022-09-27) 3.20%
1 month (2022-09-02) -2.71%
3 months (2022-07-01) -10.50%
6 months (2022-04-04) -10.96%
1 year (2021-10-04) -27.28%
2 years (2020-10-02) -29.48%
3 years (2019-10-04) 35.39
5 years (2017-10-04) 4.03%

Is Xencor stock undervalued or overvalued?

Valuing Xencor stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Xencor's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Xencor's P/E ratio

Xencor's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 70x. In other words, Xencor shares trade at around 70x recent earnings.

That's relatively high compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The high P/E ratio could mean that investors are optimistic about the outlook for the shares or simply that they're over-valued.

Xencor's EBITDA

Xencor's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $58.3 million.

The EBITDA is a measure of a Xencor's overall financial performance and is widely used to measure a its profitability.

Xencor financials

Revenue TTM $289.4 million
Operating margin TTM 17.19%
Gross profit TTM $82.6 million
Return on assets TTM 4.02%
Return on equity TTM 3.24%
Profit margin 7.77%
Book value $12.44
Market capitalisation $1.6 billion

TTM: trailing 12 months

Xencor share dividends

We're not expecting Xencor to pay a dividend over the next 12 months.

Xencor share price volatility

Over the last 12 months, Xencor's shares have ranged in value from as little as $19.355 up to $43.61. A popular way to gauge a stock's volatility is its "beta".

XNCR.US volatility(beta: 0.62)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Xencor's is 0.6157. This would suggest that Xencor's shares are less volatile than average (for this exchange).

Xencor overview

Xencor, Inc. , a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal hemoglobinuria and atypical hemolytic uremic syndrome; and Monjuvi for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma. It develops Plamotamab, a tumor-targeted antibody, which is in Phase I clinical trial to treat non-Hodgkin lymphoma; Vudalimab, a bispecific antibody, which is in Phase II clinical trial to treat metastatic castration-resistant prostate cancer and other solid tumor types; and Tidutamab that is in Phase II clinical trial to treat neuroendocrine tumors. The company is also developing XmAb306, which is in Phase I clinical trial to treat solid tumors; XmAb104 and XmAb841, which are in Phase I clinical trial to treat patients with selected solid tumors; XmAb564 that is in Phase I clinical trial to treat autoimmune diseases; AMG 509, which is in Phase I clinical trial to treat prostate cancer; XmAb819 for patients with renal cell carcinoma; and Novartis XmAb. It develops VIR-3434, which is in Phase II clinical trial for patients with hepatitis B virus infection; VIR-2482 that is in Phase 1/2 clinical trial to trat influenza A; VIR-7832, which is in Phase 1b/2a trial to treat mild-to-moderate COVID-19; and BMS-986414 + BMS-986413 is in Phase 2/3 NIH ACTIV-2 trial in treating COVID-19. The company develops AIMab7195 to reduce blood serum levels of IgE that mediates allergic responses and allergic disease; Obexelimab to treat autoimmune disease; and Xpro1595 to treat patients with Alzheimer's disease, mild cognitive impairment, and depression.

Frequently asked questions

What percentage of Xencor is owned by insiders or institutions?
Currently 0.789% of Xencor shares are held by insiders and 107.378% by institutions.
How many people work for Xencor?
Latest data suggests 254 work at Xencor.
When does the fiscal year end for Xencor?
Xencor's fiscal year ends in December.
Where is Xencor based?
Xencor's address is: 111 West Lemon Avenue, Monrovia, CA, United States, 91016
What is Xencor's ISIN number?
Xencor's international securities identification number is: US98401F1057
What is Xencor's CUSIP number?
Xencor's Committee on Uniform Securities Identification Procedures number is: 98401F105

More guides on Finder

Ask an Expert

You are about to post a question on

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and Terms of Use.

Questions and responses on are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site